MAIA Biotechnology (MAIA) stock

Cancer immunotherapies , market cap $72.9M

Targeted immunotherapies for cancer

Market cap $72.9M

$1.10

0.00%

After-hours $1.13 +2.73%

As of 6:23 PM ET after-hours, delayed 15+ min · Live for Pro members

Quality Score

-6

Poor

In its industry

#244of 291

Biotech

Checks firing

2of 14

Choppy

From 52-week high

-65.5%

Below the 200-day

MAIA's Quality Score rose 1 point on Mon, Nov 2, to -6.

Follow MAIA's trial news. Pro members can get an alert when MAIA Biotechnology files news, and see its trials, share raises, and its CEO's filings.

Get an alert when MAIA files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Why is MAIA down?

Down 16% in a year while the S&P 500 rose 12%.

Its share count rose 100.6% in a year, so each share is a smaller slice of the company.

Sources: Price history, Oct 30, 2026; Quarterly reports, Jun 30, 2026

1 more reason, free with an account →The timeline, for Pro members.

Key facts on MAIA

Key facts on MAIA
Holding it back	100.6% more shares than a year ago from Massive's market data
Latest filing	S-3, Sep 25 Registered shares for a later sale (S-3)

1 more reason behind MAIA's -6, free with an account →5 more reasons behind MAIA's -6, for Pro members.

MAIA catalysts

Coming up

1 past catalyst since 2026, with sizes and sources, for Pro members.Get in free →

What's next for MAIA, and how long its cash lasts

Its trials

A trial underway: THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLCPhase 3 · Recruiting · 300 people · main data estimated Jul 31, 2027 · NCT06908304

1 more trial, 86 filings, for Pro members.

Cash runway Jun 30 balance sheet

Under a quarter

$0 in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3, filed Aug 21, 2026)
At-the-market share sales program (S-3, filed Aug 21, 2026)

For Pro members: 8 raises and their amounts, and the share count against a year ago.

Insiders

CEO Vlad Vitoc bought 73,000 shares on Sep 14. 7 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Vlad Vitoc buys or sells

For Pro members: every trade, and Vlad Vitoc’s 16 filings and quotes.

Get an alert when MAIA files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 20 daysFDA decisionIn 20 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $385MDeramiocelFDA decision due (PDUFA)
In 20 daysFDA decisionIn 20 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $1.0BMolgramostimFDA decision due (PDUFA)
In 50 daysFDA decisionIn 50 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.9BLorundrostatFDA decision due (PDUFA)

11 more FDA dates and 102 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 143 dates, ranked →

Why MAIA scores -6

Poorfor quality, not price, 2 of 14 chart checks firingWhat the Quality Score means

-6 is below -5, off the left end of the scale.

+2Chart checks 2 of 14 firing right now, one point each
−3Long-term trend below a falling 200-⁠day average, down over one year, down over two years

Size subtracts
Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.
Insider trades adds

No effect today: Run-up, Growth, Persistence, and News.

What every line is worth, and the reason behind it, on MAIA and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 6:23 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

Alert me when MAIA's Quality Score turns up

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Here is what Pro members see.

The same page for Pro members, on AMD
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on MAIA and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

MAIA has 2 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on MAIA, and all 14 on every stock.Get in free →

MAIA RSI today: 41.3, below its 50-day and 200-day averages

Not scored

Not in the Quality Score: over 20 years of tests, 2006 to 2026, they added no edge.

RSI 1441.3
Above 30, below 50.
MACD (12, 26, 9)Above signal
Crossed above its signal line 7 sessions ago.
50-day average$1.24
The price is 11.3% below it.
200-day average$1.46
The price is 24.7% below it.
50/200 crossDeath cross
The 50-day crossed below the 200-day on Apr 28.
ADX 1410.9
Under 25, with +DI below -DI.
Support$1.06
Swing low from Oct 19, 3.6% below the price.
Resistance$1.16
Swing high from Nov 11, 2025, 5.5% above the price.
52-week high$3.19
From Jan 28, 190.0% above the price.
52-week low$0.87
From Nov 20, 2025, 20.9% below the price.
Chart patternFalling channel
Lines over the Aug 26 and Oct 9 highs and under the Sep 29 and Oct 19 lows.
Bollinger Bands (20, 2)Inside
The bands run from $1.07 to $1.22.
Volume0.5x
Against its 20-day average, for the time of day.

The deep dive on MAIA

What it does and how it makes money2 findings"10,463,685 (expires April 8, 2034), and US patent no." (10-K for fiscal 2024)SEC filing · Mar 21, 2025
Where it stands1 findingFor Pro members1 finding on where MAIA stands: its cash, debt, and share count, for Pro members
What changed in its filings3 findings"Accordingly, there is substantial doubt about the Company’s ability to continue as a going concern within one year after these financial statements are issued." (10-K for fiscal 2024)SEC filing · Mar 21, 2025"In the past, when the market price of a stock has been volatile, holders of that stock sometimes have instituted securities class action litigation against the company that issued the stock following a decline in the market price of their securities." (10-K for fiscal 2024)SEC filing · Mar 21, 2025A new heading in its "Risk Factors" this year: "Our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing." (10-K for fiscal 2024; not in fiscal 2023's)SEC filing · Mar 21, 2025, against the one of Mar 21, 2024
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades MAIA, for Pro members

4 more findings on MAIA, each with its source, for Pro membersGet in free →

How MAIA ranks in Biotech

MAIA is #244 of 291 by Quality Score.

How MAIA ranks in Biotech
1	KNSAKiniksa Pharmaceuticals International	6/14	21
2	TGTXTG Therapeutics	8/14	19
3	AMGNAmgen	5/14	19
	LXRXLexicon Pharmaceuticals		Open for its score
	LYCALycia Therapeutics		Open for its score
	MAZEMaze Therapeutics		Open for its score
	MBXMBX Biosciences		Open for its score
244	MAIAMAIA Biotechnology	2/14	-6

MAIA share count over time

101% more shares than a year earlier.

Weighted shares, quarter to Jun 30, 2026, both from one filing

Shares of MAIA outstanding, as filed
Shares outstanding	As of
60.8M	Aug 10, 2026
60.8M	May 11, 2026
60.7M	Mar 23, 2026
37M	Nov 7, 2025

Offerings, shelves, and splits of MAIA, from its filings
From its filings	Filed
Registered shares for a later sale (S-3)	Sep 25, 2026
Registered shares for a later sale (S-3)	Aug 21, 2026
Set up an at-the-market program for up to $11.2M of shares, about 15% of its market value	May 14, 2026
Raised $30M in a sale of shares, about 41% of its market value	Mar 4, 2026

6 more offerings on file, for Pro members.

Insiders trading MAIA

MAIA insider trades

4 insiders bought $556K across 10 filings in the last 6 months. No open-⁠market sales on record. The newest:

BuyVlad Vitoc$100KChief Executive Officerat $1.37 on Sep 14, filed Sep 15

BuyVlad VitocChief Executive Officer$100Kat $1.37 on Sep 14, filed Sep 15

All 10 insider filings on MAIA from the last six months, for Pro members.Get in free →

All MAIA insider trades

MAIA's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Vlad VitocChief Executive Officer · 6 trades
Sergei GryaznovChief Scientific Officer · 1 trade
Ramiro GuerreroDirector · 6 trades
Stan SmithDirector · 6 trades
Cristian LuputDirector · 3 trades
Steven M. ChaoukiDirector · 1 trade
Ngar Yee LouieDirector · 1 trade
Stan SmithDirector · 1 trade

See insider trades by person

Which ETFs hold MAIA?

In ETFs: MAIA is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About MAIA Biotechnology

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

13 employeesChicago, ILmaiabiotech.com

What MAIA Biotechnology says it competes with

“The biotechnology industry is characterized by a rapid evolution of technologies, significant competition and strong defense of intellectual property.”

From its annual report, SEC filing · Mar 21, 2025

2 more sentences and what it says it does, for Pro membersGet in free →

MAIA's score card

MAIA Biotechnology (MAIA): Quality Score -6, Poor, #244 of 291 in Biotech, with its price, on Breakaway — The picture a link to this page shows when it is shared.

Pro members see every line of every stock's score.

What would turn MAIA's score around: 8 things
12 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawaySep 15Vlad Vitoc bought MAIA$100K at $1.37, filed Sep 15

Alerts are optional.

See MAIA's 14 chart checks

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Straight Answers

As of Nov 2, 2026: MAIA's Quality Score is -6 (Poor), #244 of 291 in Biotech. Insiders bought $556K in the last 6 months (Form 4).

Is MAIA a good stock to buy? What its Quality Score says

MAIA scores -6 today, which Breakaway calls Poor. It is #244 of 291 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 16% in a year while the S&P 500 rose 12%. Cash lasts about 0 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is MAIA's Quality Score?

MAIA scores -6 today, which Breakaway calls Poor (below zero). That is #244 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind MAIA's -6.

Are insiders buying MAIA?

4 insiders bought $556K across 10 filings in the last 6 months. No open-⁠market sales on record. The newest is Vlad Vitoc, Chief Executive Officer, who bought $100K on Sep 14. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.